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Summary 
An overview of the links between the Hypothalamic-Pituitary-Adrenal (HPA) axis and psychiatric 
disorders is presented. The current treatments are outlined, indicating that they are insufficient to 
meet the needs of those that suffer from these affective disorders. Therefore, there is an urgent need 
for the generation of new therapeutics, in particular, against new targets. The association of the 
corticotrophin releasing factor (CRF) and the HPA axis indicates that CRF antagonists should be 




It is estimated that 22% of Americans aged 18 years and older suffer from some form of 
diagnosable mental disability [1]. Of the 10 leading causes of disability in the US, four are 
psychiatric diseases and include unipolar disorder (UPD), bipolar disorder (BPD), anxiety and 
anorexia nervosa [2]. These figures have been mirrored in other developed countries such as the 
United Kingdom and Australia where approximately 20% of the adult population suffer from some 
form of psychiatric disability [3].  
 
Current treatments for these conditions are barely adequate and there is the need for the 
development of a new generation of novel psychiatric pharmaceutical agents acting via alternate 
mechanisms. Several new hypotheses have been formulated in recent times in response to the 
ongoing inadequacy of current psychiatric treatments. Many of these directly suspect the 
dysregulation of the bodies stress system, the hypothalamic-pituitary-adrenal (HPA) axis, as being 
responsible for the induction and prolongation of psychiatric diseases [4]. Subsequently these 
hypotheses have implicated the HPA axis components; corticotropin-releasing factor (CRF), 
glucocorticoids and cyclic adenosine monophosphate (cAMP) response element binding proteins 
(CREB) as subsystems that are potentially responsible for psychiatric malfunctions [5].  
 
Although the HPA axis has been studied extensively since the 1950’s, only recent breakthroughs in 
biotechnology and endocrinology have resulted in the successful cloning of CRF and its receptors 
[6]. Thus allowing the means to closely study and monitor their characteristics.  
 
Recent studies [7] analysing the HPA axis and its involvement in psychiatric diseases have 
identified the following unusual symptoms in patients; high concentrations of CRF in the central 
nervous system (CNS), abnormal results to corticoid response tests, hyperactive CRF neuron 
activity and abnormal CRF receptor expression patterns. This has justified initial scientific efforts to 
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look more closely at the role of CRF in the induction HPA dysregulation [7]. The increasing 
evidence that CRF and the HPA axis play definitive roles in many psychological disabilities has led 
to a focus on CRF antagonists as a novel means to treat these disorders [8].  
 
This review will discuss the current knowledge of CRF and its receptors, examine evidence put 
forward to support the CRF-HPA dysregulation hypothesis while finally commenting on recent 




Undoubtedly an extensive range of psychiatric conditions will potentially benefit from CRF based 
antagonist treatment. Even though a wide range of psychiatric disorders exist, discussion will focus 
on affective, anxiety and narcotic dependence based conditions. 
 
Affective disorders: 
Affective disorders are the most common form of psychiatric condition present in modern day 
society [9]. While often being a preluding or partnered condition for numerous other disorders such 
as drug addiction, obsessive compulsive disorder (OCD), anxiety and anorexia, affective disorders 
are generally classified as depression, which is further divided into two subtypes; bi-polar and uni-
polar disorders. 
 
Bi-polar disorder, more commonly known as manic depression, is a form of mood disorder 
characterised by brief periods of euphoria followed by alternating periods of severe depression. The 
manic or euphoric phases are characterised by extreme hyperactivity, restlessness and feelings of 
great self importance often accompanied by a denial of their condition [7, 9, 10]. The disease occurs 
in approximately 1.6% of the world population and is diagnosed equally between men and women 
[10].  
 
Uni-polar depression differs from its bi-polar counterpart as no mania spells are experienced by the 
patient. Depressive episodes follow a more continuous unrelenting pattern with intermittent periods 
of normal emotional behaviour. Additional symptoms include torpidity due to diminished energy 
levels, low self esteem and reduced motivation to partake in normal activities [7, 9]. This can lead 
to a breakdown of social and family ties and reduced productivity in the workforce, with an 
estimated cost in the US alone of $55 billion per year arising from depression-related illnesses [10]. 
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Anxiety: 
Anxiety disorders encompass a wide range of conditions such as general anxiety disorders (GAD), 
panic disorder, post traumatic stress disorder, phobias and Tourette syndrome [9, 11]. These 
disorders are characterized by patients experiencing fear or constant episodes of anxiety over 
matters which do not necessarily require or provoke any real cause for anxiety. Anxiety disorders 
cause symptoms such as chest pains, dizziness and hot flashes during panic attack episodes, 
increased heart rate, poor concentration and irrational behaviour. One in every eight Americans 




Drug addiction is defined as the uncontrollable desire to take a drug accompanied by diminished 
control in limiting its intake [12]. Drug addiction, also known as drug dependency, can involve both 
physiological and psychological dependence. Physiological dependence is caused by alterations to 
the user’s physiology and metabolic pathways resulting in adaptation requiring the drug to be 
present for continued function. Psychological dependence is when patients assume they need a drug 
in order to properly function where in fact no physiological dependence exists [11, 12]. Drug 
addiction is usually more prevalent in males than females however the incidence of female 
addiction is rising [12].  
 
Narcotic addiction or dependence can result in increased tolerance barriers by physiological 
adaptations by the brain, e.g. desensitisation through reduction in receptor populations [13]. 
Unfortunately this can lead to the use of high doses of narcotic substances which can give rise to 
permanent organ damage and/or death. Some of the known addiction or dependency side effects 
include; social isolation, poor concentration, aggressive behaviour and irrational thinking.  
 
In the US, 23 million adults are believed to be repeat substance offenders [7, 10]. Drug addiction in 
the US is estimated to cost over $67 billion dollars a year in social and medical costs for treatment 
of illicit drug users [12]. 
 
In summary affective, anxiety and substance abuse are three classes of psychiatric disorders with 
unique mechanisms. There is growing evidence to support that these three conditions share a 
common involvement of CRF and the HPA. 
 
Current Treatments of Psychiatric Disorders  
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Current treatments have been designed according to the monoamine theory, whereby focus is placed 
on regulating the production and reuptake of neurotransmitters such serotonin, norepinephrine and 
dopamine, which have been attributed to play a significant role in depression [14]. Unfortunately, as 
well as being effective, these agents also have numerous limitations. Initial treatment only cures 
approximately 50% of patients with one in three not responding to standard treatments in the long 
term [15]. 
 
Selective Serotonin Reuptake Inhibitors (SSRIs) are currently the most prescribed drug family for 
treatment against depression and anxiety related illnesses [16]. Typically SSRI drug therapy takes 
4-6 weeks to show any positive results, and is preferred for depression patients as the risks 
associated with overdosing are greatly reduced [16, 17]. Once symptoms subside, antidepressant 
therapy is continued for up to 6-9 months [15-17]. Such lengthy medication regimes are expensive 
and patient discipline in continuing treatment for this long can waver [16]. SSRI regimes are 
unfortunately associated with draw backs such as nausea, insomnia, and low libido which can 
impede sexual functions [18].  
 
Monoamine Oxidase Inhibitors (MAOIs) were the first antidepressants introduced into mainstream 
society and have also been adopted to treat anxiety patients. These drugs are still considered 
secondary option treatments for patients whom fail to respond to alternative first wave therapeutics 
for anxiety and depression [16]. MAOIs initiate the rapid and sustained release of serotonin (5-HT) 
in the brain by inhibiting monoamine oxidase. Common side effects associated with MOAI therapy 
are; hypotension, tremors, insomnia, convulsions while in some cases they can induce dangerous 
drug-to-drug and drug-food interactions causing serious harm [18,19]. As a result patients are often 
forced to comply with strict diets and are prevented from taking many other pharmaceutical agents 
[19].  
 
Tricyclic antidepressants (TCA) drug therapy is known to have similar results to SSRI treatments 
[17], however they usually require a longer period for their onset of action compared to SSRI based 
drugs [15]. Their method of action is primarily to prevent the reuptake of amines by nerve 
terminals. TCA therapies typically cause blurred vision and constipation. In addition, patients with 
heart complications are strictly prohibited from using these drugs as they can cause arrhythmias 
[20]. 
 
Beta-Blockers and benzodiazepines are fast-acting short term anxiety treatment options requiring 
unfavourable repeated dosing applications to prolong therapeutic effects [16]. Beta-Blockers are not 
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prescribed to patients with asthma or heart complications as they can amplify these conditions [21]. 
Benzodiazepines are addictive and cause drowsiness, fatigue and poor memory making their usage 
highly unfavourable [22]. 
 
Corticotropin Releasing Factor (CRF) 
 
CRF is the hypothalamic peptide Fig. (1) that stimulates adrenocorticotropin hormone (ACTH) 
release from the pituitary gland which in turn induces cortisol release as a mechanism for organisms 
to deal with stress inducing situations [23]. CRF is a small 41 amino acid peptide synthesized and 
released from multiple regions of the brain including the paraventricular nucleus (PVN), 
hypothalamus and the locus ceruleus (LC) [24]. CRF is the initiator of the HPA axis and determines 
the rate at which the HPA axis operates. This peptide has also been associated with secondary roles 





Figure 1: Amino acid sequence of CRF. 
 
 
Distribution of CRF: 
CRF synthesis and storage bodies are densely populated within the paraventricular nucleus (PVN) 
of the hypothalamus and amygdala [26]. Production of CRF is stimulated through various neuronal 
peptides and transmitters including acetylcholine, histamine, serotonin and many other common 
neuronal messengers [27]. The PVN and amygdala neuronal bodies distribute their axons to the 
capillaries in the median eminence, lower brain steam, cerebral cortex and spinal cord [28]. High 
concentrations of CRF are present in the locus caeruleus and the central nucleus of the amygdala, 
both of which are involved in anxiety and stress behaviour regulation and are stimulated by CRF 
neurons in the PVN. [4, 23, 29]. Additional CRF containing bodies are present in the neocortex and 
bed nucleus of the stria terminalis [29].  
 
Peripheral tissues including the stomach, pancreas, small intestine, lymphocytes, placenta and the 
testes also have demonstrated a significant CRF presence [23]. The identification of CRF in these 
non-CNS neuronal bodies suggests its wide range of influence in numerous physiological systems 
such as immunity, digestion and reproduction in addition to the stress axis [26-28]. 
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CRF Receptors: 
Currently 2 types of CRF receptors have been classed and identified, CRF1 receptors (CRF1R) and 
CRF2 receptors (CRF2R). Both receptors have their own unique gene and custom distribution within 
the body. CRF1R and CRF2R both share close homology with one another and belong to the class B 
subtype of G-protein coupled receptors Fig. (2) [28].  
 
 
Figure 2: Amino acid sequences for corticotropin releasing hormone CRF1, CRF2α, CRF2β and 
CRF2γ receptor types. The seven transmembrane domains are shown where the arrows indicate the 
divergence between the CRF1 and the various CRF2 receptors. Glycolysation sites have been 
indicated by ψ while ▲ indicate protein kinase C binding sides. 
 
 
The third intracellular loop within all CRF receptors is thought to be the interactive region between 
the receptor and the coupled G-protein. This hypothesis is supported by the fact that the third 
intracellular loop is identical across all isoforms of the CRF receptor [26, 28]. CRF receptors are 
positively regulated via cAMP accumulation in response to CRF agonist binding which then relays 
the hormonal signal [29].  
 
CRF1 receptors (CRF1R): 
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The CRF1R is 415 amino acids in length, its seven transmembrane domains contain 5 N-linked 
glycolysation sites and 2 potential phosphorylation sites for protein kinase C (PKC) in the C-
terminal tail. CRF1R also has casein kinase II and protein kinase Fig. (2). A phosphorylation sites in 
the 3rd extracellular loop, however their purpose remains unclear [30]. A variety of CRF1R spliced 
variants exist and have been classified CRF1a through to CRF1h [4]. These variants have not shown 
any significant alternative activity compared to CRF1aR [4].  
 
CRF1R shows high distribution within the brain and other sections of the CNS. Most dense areas of 
distribution are in the cerebral cortex, olfactory bulb, medial septum, hippocampus, amygdala and 
the pituitary [29, 31, 32]. Through autoradiography localisation studies it has been discovered that 
CRF1R distribution patterns in different compartments of the brain vary [31]. For instance CRF1R 
within the anterior pituitary seem to be clustered, mirroring the distribution of corticotrophs. This 
contrasts CRF1R distribution within the intermediate lobe where the receptors are localised evenly 
across the lobe, following the distribution patterns of POMC producing cells. [33] 
 
The distribution patterns of CRF1R within the brain and peripheral tissues support current 
hypotheses suggesting CRF is responsible for POMC peptide regulation and secretion from the 
anterior and intermediate pituitary lobes [23, 33]. 
 
CRF2 Receptors (CRF2R): 
The second splice variant of the CRF receptor family, CRF2R, can be subdivided into 3 isoforms 
CRF2α CRF2β and CRF2γ. Both α and β isoforms have been isolated in rats, mice and humans 
however CRF22γR has only been identified in humans [26, 34]. 
 
CRF2 receptors, unlike their CRF1R counterparts, have a wide distribution, encompassing a broader 
range of tissues. Studies showed CRF2R mRNA is expressed in the lateral septal nuclei, 
hypothalamic nuclei, in the bed nucleus of the stria terminals along with amygdaloid nuclei, though 
not at the same intensity as CRF1R [31]. Furthermore these studies went on to establish that CRF2γR 
are distributed mainly in areas of the CNS whereas the CRF2αR and CRF2βR have been identified 
primarily in non-neuronal and peripheral tissues such as the cerebral arterioles and the choroid 
plexus of the ventricular system [34]. CRF2βR are also found in the heart, GI tract, skeletal muscle 
and lungs [4, 23]. Due to the dense distribution of CRF2βR within the cerebral arterioles and the 
choroid plexus of the ventricular system it leads to the potential hypotheses that CRF2βR are in fact 
linked to a modulation role for cerebral blood flow [33]. 
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CRF from gene to protein: 
The human CRF gene is assembled by 2 exons 686-800 base pairs in length and has been mapped 
on Chromosome 8 (8q13) [23]. The translation of the CRF gene produces a 196 amino acid (aa) 
pre-proCRF molecule which is enzymatically treated within the rough endoplasmic reticulum to 
form proCRF which undergoes additional post-translational alterations [35, 36]. Further alterations 
are performed in the trans-Golgi network to produce the final 41 aa CRF peptide [36].  
 
CRF production is regulated through the protein kinase pathway. Studies where cAMP has been 
administered to perfused rat hypothalami have shown marked increases in CRF secretion [31]. 
cAMP is thought to interact with a cAMP responsive element (CRE) region approximately 200 base 
pairs upstream from the CRF gene, promoting gene translation [35, 36]. Examination of CRF and 
the HPA axis has shown that CRF initiated release of glucocorticoids from the adrenal glands 
results in a negative feedback regulation mechanism, where glucocorticoids inhibit CRF production 
by interfering with cAMP-response element binding protein CREB/CRE controlled gene 
transcription process [35-37]. 
 
HPA Axis and stress response: 
The HPA axis is the infrastructure of the body which regulates the stress response. CRF neurons 
within the PVN of the hypothalamus are the primary source of CRF within the CNS. Release of 
CRF stimulates the anterior pituitary to release ACTH, which is transported through the blood 
stream to the adrenal cortex to initiate the synthesis and secretion of cortisol, a glucocorticoid [38].  
 
Regulation of the HPA axis is controlled by an intricate network of neuronal and hormonal 
pathways including the hippocampus, the amygdala, glucocorticoid peptides and monoamine 
neurotransmitters [38, 39]. Activation of the HPA axis results in higher locomotive activity, reduced 
sex drive, low affinity for food, redirected blood flow from the gastro intestinal tract to skeletal 
muscle, increased sensory sensitivity, increased heart rate and raised blood sugar levels. These 
adaptations which help an individual respond to a stress event [39, 40]. 
 
A stress event lasting longer than a few minutes results in increased levels of cortisol being released 
from the adrenal cortex. CRF and ACTH in healthy individuals are released only in short 
intermittent bursts resulting in controlled cortisol release [41]. Thus, in stressful situations, a 
moderate cortisol level is maintained in the bloodstream to main stable physiological function and 
homeostasis in the HPA axis [41]. 
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A stress event may be emotionally, physically or chemically induced which initiates CRF secretion 
over the affected time period, allowing for beneficial physiological adaptations i.e. increased 
sensory sensitivity which allows individual organisms to respond adequately to a stressful situation 
[39]. Prolonged stress influences are thought to over-stimulate the HPA axis causing hypersecretion 
of CRF which ultimately, if left untreated, leads to HPA dysregulation potentially promoting the 
onset of psychiatric disorders [41].  
 
Support for HPA Dysregulation Theory  
Numerous studies have indicated that individuals suffering from anxiety and/or depression possess 
a sustained unregulated HPA axis. The hyperactivity of the HPA axis has been shown to exacerbate 
the additional secretion of CRF and subsequently ACTH. This dysregulation is the assumed cause 
of hypercortisolemia, a symptom observed in numerous psychiatric related disabilities [38]. 
 
Post Mortem Examinations: 
Post mortem analysis of brain tissues obtained from suicide victims who were suffering from long 
term depression showed a significant reduction in CRF receptor sites in various regions of the brain, 
most noticeably in the cerebral cortex [4]. The emerging pattern of reduced receptor sites suggested 
the presence of a mechanism attempting to compensate for the hypersecretion of CRF [42]. Further 
study into this phenomenon led to the discovery that suicide victims also had a 400% increase in 
CRF producing neurons within the PVN and a dramatic increase in CRF mRNA expression 
compared to standard controls [43]. Therefore a mechanism in depressed patients exists which is 
responsible for the recruitment of additional neuronal cells to produce CRF. This suggests 
dysregulation in the HPA axis as CRF secretion is uninhibited in these patients [44]. Such drastic 
increases of CRF secretion would no doubt lead to higher concentrations of ACTH and cortisol in 
the blood stream and CNS.  
 
CRF in cerebral spinal fluid (CSF) and blood plasma: 
Following initial indications that CRF might be involved in depression and anxiety disorders [45] 
further analyses of CRF concentrations were employed. Due to the difficulty of obtaining CRF 
concentration data directly from the brain, cerebral spinal fluid (CSF) was used to gauge CRF 
concentrations where a clear correlation between diseased states and CRF concentrations in the CSF 
was established [46]. Results showed there was a tangible increase in CSF CRF concentrations in 
patients who were suffering from depression, anxiety and dementia when compared to healthy 
controls [45, 46]. In addition results have also indicated increased levels of CRF in the blood stream 
among depressed patients [23], however these results have not been replicated in follow up studies 
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[33, 45-46]. The increased amount of CRF discovered in varying bodily fluid systems across 
different psychiatric diseases suggests the presence of CRF hypersecretion, thus indicating a 
dysregulated HPA axis.  
 
Anxiety effects of CRF: 
CRF neurons are believed to encompass numerous additional functions including the influence on 
proopiomelanocortin (POMC) synthesis through the release of CRF into the portal blood stream 
[47]. POMC is converted to melanocortin which is known to inhibit feeding behaviour and induce 
weight loss [47-49]. When an excess of POMC is produced the side effects mimic those observed in 
anorexia nervosa patients [47-49]. Observation of rats undergoing chronic exposure to CRF 
indicated the manifestation of several response adaptations including hyperexcitability, fear and 
other anxiogenic behaviours normally associated with anxiety [50-52]. These initial trials were then 
further extended by injecting urocortin, a CRF receptor agonist, into central nucleus of the 
amygdala, hypothesised as being the key body involved in signal transmissions responsible for the 
onset of anxiety disorders [51]. Results provided evidence of severe anxiogenic symptoms as a 
direct result of the chronic agonist exposure. 
 
Antisense oligodeoxynucleotide (ODN’s) tests provided the opportunity to observe if non-CRF 
producing rats were still liable to suffer from stress or anxiety behaviour [53]. ODN exploited rats 
had significantly decreased anxiety like behaviour and showed a reduction in stress. In reply to 
these investigations an alternative approach was trialled whereby CRF was over-expressed using 
transgenic mice, mimicking the excess CRF secretion causing HPA dysregulation as observed in 
psychiatric patients. As expected, the over-production of CRF in the transgenic mice caused severe 
anxious behaviour [52-53]. Extended trials then observed the effect of CRF antagonists upon these 
test subjects. As hoped a reversal of anxiety and depression symptoms occurred [23, 33]. By 
creating a CRF hypersecretion model in rodents reflecting human observations, these experiments 
were able to provide strong supporting evidence linking anxiety to HPA-CRF dysregulation. 
 
Effects of current pharmaceutical agents on CRF: 
It has been indicated that current antidepressants may produce their therapeutic effects partly 
through the regulation of the HPA-CRF system [14]. Such a hypothesis was first considered when 
exposing rats to imipramine, a tricyclic antidepressant (TCA) and CP-154526, a CRF1R antagonist, 
resulted in decreased immobility indicating a reduction of CRF influence was linked to a reversal of 
anxiety and depression through classical treatments [20]. These trials were further expanded where 
it was discovered that rats which had undergone imipramine treatment for two weeks showed signs 
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of increased glucocorticoid receptor (GR) immunoreactivity [17]. This change allowed for an 
increase in the glucocorticoid negative feedback mechanism in the HPA axis resulting in a 
reduction of CRF mRNA in various regions of the brain most importantly the hippocampus, 
hypothalamus and the pituitary [40].  
 
Additional evidence proposing alternate mechanisms of action came to light when high numbers of 
CRF receptors were observed in rat brains which had undergone chronic imipramine exposure, 
suggesting that CRF production had been impeded, forcing the body to compensate by increasing 
binding sites [15, 17]. Alternatively links between antidepressant use and a reduction in CRFR in 
the anterior pituitary were also established when reductions of CRF1R mRNA expression in the 
amygdala was observed in rats after exposure to SSRI treatment [14]. Further studies subsequently 
indicated the increase in GR mRNA expression in the hippocampus caused a suspected increase in 
HPA axis inhibition as a result of antidepressant usage [16].  
 
Similar studies have been performed on current anti-anxiety treatments, implying they inhibit the 
HPA axis. Acute benzodiazepine administration has been shown to result in reduction in CRF 
concentration in the locus coeruleus, amygdala and the pyriform cortex, all of which are associated 
with stress behaviour [29].  
 
Evidence provided in these monoamine studies has identified many inconsistencies in monoamine 
theory, on which most modern day antidepressants and anti-anxiety medications are founded upon 
[14, 16]. Most notably, compounds known to significantly enhance monoamine transmission, which 
is the suspected mechanism of action of monoamine based treatments, had little to no therapeutic 
effect in depressed or anxiety patients. Neurotransmitter concentrations between groups taking 
standard medications and the new transmission enhancing drugs were similar, however the new 
compounds had no therapeutic effect [14, 16, 17]. This suggests that current antidepressant and 
anti-anxiety medications do not enact their therapeutic benefits through monoamine pathways. In 
addition it is yet to be explained why certain clinical treatments currently in use show minimal 
effects on monoamine transmission pathways, though are potent and therapeutically effective 
against depression and anxiety. Furthermore some antidepressant drugs have delayed therapeutic 
benefits which, interestingly coincides with an apparent inhibition rather than excitatory effects on 
monoaminergic transmission [16].  
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These conflicting results suggest that perhaps the current therapies are not primarily enacting their 
therapeutic properties through monoamine neuropeptide pathways but also via other mechanisms 
related to HPA regulation.  
 
Evidence of HPA dysregulation in substance abusers: 
Considerable evidence has indicated that acute administration of psychostimulants causes a stress 
like activation of the HPA axis in rodents [54]. Amphetamine exposure tests stimulated high rates 
of ACTH release using dosages as low as 6 μg/kg while cocaine induced HPA activation increased 
cortisol levels within 10 minutes of injection [54, 55]. Moreover cocaine use in rodents was found 
to release CRF from hypothalamic tissue in vitro; this demonstrates that psychostimulant drugs 
mediate their effects on the HPA through CRF to induce stress events in the brain. This 
subsequently caused abnormal increases of ACTH and cortisol in the CSF and blood stream [54].  
 
Broader studies testing the impact of alcohol and opioids demonstrated similar results suggesting 
that many forms of substance abuse cause damage to the HPA system where prolonged exposure 
would induce long term HPA dysregulation [12]. Chronic administration of cocaine in subsequent 
studies was found to successfully cause HPA over-stimulation implicating the inability of the HPA 
axis to raise tolerance response barriers against prolonged cocaine abuse [56]. Protracted use would 
likely induce glucocorticoid burden leading to organ system damage as seen in chronic cocaine 
users [12].  
 
The initial CRF response to alcohol was a 3 fold increase in CRF concentration in the CSF. 
However the development of a tolerance barrier was suspected as PVN CRF neurons showed a 
reduction in CRF secretion. This contradicted observations in the pituitary which demonstrated a 2 
fold increase in CRF secretion. Conclusions from the study determined that long term alcohol 
exposure engendered atypical HPA hyperactivity.  
 
Substance abusers in withdrawal commonly express the symptoms of negative and illogical 
behaviour such as dysphoria, depression and irritability. Clinical and non-clinical research has 
indicated that stress, depression and negative mood states are strong confounding factors that 
increase the likelihood of perpetuation of drug use in substance abusers [12, 57]. Clinical trials 
provided circumstantial evidence by demonstrating that heroin experienced mice displayed “drug-
seeking” behaviour after being exposed to a stress event [55, 57]. Survey statistics established that 
many substance abusers were unable to break addictions due to psychological stress, depression and 
negative mood states which derived from HPA dysregulation.  
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The data obtained from these investigations leads to a theory that substance abuse is potentially a 
means of self-medication to stave off depression or negative mood states. Ironically the same 
behaviour demonstrated by narcotic addicts increases the stress placed on the brain resulting in a 
never ending cycle of CFR secretion and HPA dysregulation [56]. 
 
Dexamethasone tests and glucocorticoids:  
The condition of hypercorticolism, the hypersecretion of cortisol, is a common trait seen in patients 
suffering from depression, anxiety and substance abuse. This condition relates to the abnormal 
secretion of cortisol due to excessive CRF activation of the HPA axis. Psychiatric patients 
uniformly fail to show any lasting response to the dexamethasone suppression tests which should 
inhibit CRF release. This suggests that increased glucocorticoidal concentrations by the introduction 
of dexamethasone did not aid in the inhibition of CRF release as expected. Two hypotheses put 
forward suggested the potential inception of a yet to be identified resistance mechanism against 
standard negative feed-back or the manifestation of an overactive HPA axis resulting in a HPA 
drive which was able to easily surpass any cortisol inhibition message [36].  
 
CRF challenge tests were performed by injecting CRF and urocortin, a CRF antagonist into 
psychiatric and control patients to analyse the ACTH production response. Results showed diseased 
patients had a blunted ACTH response compared to control groups, suggesting that this was caused 
by down regulation of the pituitary CRH1Rs in diseased patients as indicated in previous post 
mortem studies. Though control groups had higher rates of ACTH synthesis in the short term during 
the experiment, diseased patients, still had a higher ACTH secretion rate in the long term due to the 
constant hypersecretion of CRF. 
 
Investigations into hypercortisolism and its role in HPA dysregulation revealed that extreme cortisol 
concentrations lead to the increased expression of CRF mRNA in the bed nucleus of the stria 
terminalis, amygdala and PVN [4, 23]. These results provide a possible explanation for the 400% 
increase in CRF secreting neurons observed in the post mortem studies described earlier in this 
chapter. These observations that implicate the very pathway meant to inhibit CRF production can be 
a contributing instigator of additional CRF secretion. Thus, this suggests the presence of a positive 
feedback mechanism promoting HPA dysregulation and hypersecretion of CRF is established in 
diseased patients.  
 
Novel CRF antagonists 
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With the wealth of evidence that has amassed implicating the role of the HPA-CRF system in the 
pathogenesis of affective, anxiety and drug related psychiatric conditions, attention has turned to 
seek a new generation of pharmaceutical agents targeting CRF receptors. The structural entities that 
possess CRF antagonistic activity have been reviewed,[58,59,60] however some of the more 
common and important are summarised here.  
 
Initial attempts at CRF antagonist development resulted in the discovery of the oxopyrazoline 
thiocyanates (I) Fig. (3) [61], which showed weak activity against CRF (3-70 mM/L). Further 
adaptations led to the development of five-membered ring systems focusing on the thiazole core (II, 
III) Fig. (3) framework which has resulted in improved activity (15 nM/L) [61]. Improvements 




Figure 3: Examples of CRF antagonists containing a five-membered heterocyclic core unit. 
 
CP-154,526 (IV) Fig (4) was the first potent non-peptide CRF1R specific antagonist to be 
developed [62]. This antagonist has demonstrated a binding preference for CRF1R having a binding 
activity of 2.7 nmol/L when tested in rat PVN neuronal tissue. Trials using this antagonist have 
shown it to be a potent inhibiter of CRF activation on the HPA axis reducing stress responses and 
also attenuating drug seeking behaviour in rodents [61] and human trials of this compound are 
imminent.  
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Figure 4: Selective CRF1R antagonists CP-154,526 (IV) and R121929 (V) 
 
These alternative additional fused six-membered ring systems, namely aniline-pyrimidines 
structures such as R121919 (V) Fig (4) is a selective CRF1R antagonist which has shown 
remarkable benefits over previously synthesised compounds in its class due to increased solubility 
and its capacity to easily penetrate the blood brain barrier [63, 64]. Human clinical trials have 
shown that this compound improves anxiety and depression states. Clinical trials also provided 
evidence indicating its ability to attenuate HPA axis hyperactivity while not entirely inhibiting 
ACTH or cortisol release allowing for regular HPA related functions to continue unhampered [63, 
64]. Beneficial outcomes have allowed R12919 (V) to move on to larger clinical trials however, 
these were discontinued due to hepatoxicity. [65] Research into the CRF and the HPA axis 
continues with initial steps giving more support to the HPA dysregulation hypothesis.  
 
Conclusion  
Compounding evidence from a wide range of pre-clinical and clinical studies has produced support 
for the HPA axis hypothesis suggesting hypersecretion of CRF has a profound effect in initiating 
psychiatric disabilities ranging from affective disorders to substance abuse. The source of increased 
CRF has been delegated to the hyperactivity of CRF releasing neurons within the amygdala, PVN 
and the pituitary causing increased rates of ACTH and cortisol secretion in rodents, primates and 
humans. In reply to these results drug developers have shown that experimental CRF antagonists 




[1] D. A. Regier, W. E. Narrow, D. S. Rae, R. W. Manderscheid, B. Z. Locke, F. K. Goodwin, 
Arch. Gen. Psychiat. 1993, 50, 85-94. 
  17 
[2] The Numbers Count: Mental Disorders in America 
http://www.nimh.nih.gov/publicat/numbers.cfm (28/3/2006) 
[3] Social Inequalities and the Distribution of the Common Mental Disorders. Ed. T. Fryers, R. 
Jenkins, D. Melzer, 2 Ed., Taylor & Francis: New York, 2004. 
[4] A. J. Mitchell, Neurosci. Biobehav. Rev. 1998, 22, 635-651. 
[5] M. Pelleymounter, M. Joppa, M. Carmouche, M. J. Cullen, B. Brown, B. Murphy, D. E. 
Grigoriadis, N. Ling, A. C. Foster, J. Pharm. Exp. Ther. 2000, 293, 799-806. 
[6] T. W. Lovenberg, D. T. Chalmers, L. Changlu, E. B. De Souza, Endocrinol. 1995, 136, 4139-
4142. 
[7] R. L. Leahy, S. J. Holland, Treatment Plans and Interventions for Depression and Anxiety 
Disorders. 1st Ed, The Guilford Press: New York, 2000. 
[8] D. K. Grammatopoulos, G. P. Chrousos, Trends Endocrin. Met. 2002, 13, 436-444. 
[9] S. M. Stahl, Essential Psychopharmacology. 3rd Ed., Cambridge University Press: Cambridge, 
1998. 
[10] K. Lambert, C. H. Kinsley, Clinical Neuroscience. 1st Ed., Worth Publishers: New York, 2004 
[11] M. Townsend, Essentials of Psychiatric Mental Health Nursing. 3rd Ed., F.A. Davis: 
Philadelphia, 2005 
[12] Z. Sarnyai, Y. Shaham, S. C. Heinrichs, Pharmacol. Rev. 2001, 53 (2), 209-243. 
[13] N. R. Carlon, Foundations of Physiological Psychology. 6th Ed., Pearson Education: Boston, 
2005 
[14] G. Baker, W. Dewhurst, Biochemical Theories of Affective Disorders. 2 Ed., Croom Helm: 
London, 1985 
[15] C. Nmeroff, Sci. Am. 1998 278, 28-35. 
[16] H. Rang, M. Dale, J. Ritter, P. K. Moore, Pharmacology. 5th Ed., Churchill Livingstone: 
Loanhead, 2003. 
[17] A. Frazer, J. Clin. Psychopharm. 1997, 17, Suppl 1, 2S-18S. 
[18] M. Wong, J. Licinio, Nat. Rev. Neurosci. 2001, 2, 343-351. 
[19] A. Savinelli, Multidisciplinary Association for Psychedelic Studies Letters 1995, 6 (1), 58. 
[20] R. Pies, J. Clin. Psychopharm. 1995, 15, 303-305. 
[21] I. Maidment, Psychiatr. Bull. 2000, 24, 348-351. 
[22] C. Salzman, J. Psychiat. Res. 1993, 27, Suppl 1, 97-110. 
[23] B. DeSouza, D. Grigoriadis, Neuropsycopharmacology: The Fifth Generation progress. 5 Ed., 
2002, p 19. 
[24] M. P. Conn, H. M. Goodman, A. Cherrington, L. S. Jefferson, J. L. Kostyo, The Endocrine 
System. 1st Ed., Oxford University Press: New York, 2001 
  18 
[25] D. K. Grammatapoulos, E. W. Hillhouse, Lancet 1999, 354, 1546-1549. 
[26] G. Aguilera, M. A. Millan, R. L. Hauger, Annal. NY Acad. Sci. 1987, 512, 48-66. 
[27] E. Ur, A. Grossman, Acta Endocrinol. 1992, 127, 193-199. 
[28] T. L. Bale, W. W. Vale, Ann. Rev. Pharmacol. 2004, 44, 525-557. 
[29] P. J. Gilligan, D. W. Robertson, R. C. Zaczek, J. Med. Chem. 2000, 43, 1641-1660. 
[30] E. B. De Souza, J. Neurosci. 1987, 7, 88-100. 
[31] D. E. Grigoriadis, X. J. Liu, J. Vaughn, Mol. Pharmacol. 1996, 50, 679-686. 
[32] E. B. De Souza, E. L. Webster, D. E. Grigoriadis, D. E. Tracey, Psychopharmacol. Bull. 1989, 
25, 299-305. 
[33] F. Holsboer, J. Psychiat. Res. 1998, 33, 181-214. 
[34] D. N. Orth, Endocr. Rev. 1992, 13, 164-191. 
[35] S. P. Malkoski, R. I. Dorin, Mol. Endocrinol. 1999, 13, 1629-1644. 
[36] M. J. Perone, C. A. Murray, O. A. Brown, S. Gibson, A. White, E. A. Linton, A. V. Perkins, P. 
R. Lowenstein, M. G. Castro, Mol. Cell Endocrinol. 1998, 142, 191-202. 
[37] G. Aguilera, Trends Endocrin. Met., 1998, 9, 329-336. 
[38] E. J. Nestler, M. Barrot, R. J. Di Leone, A. J. Eisch, S. J. Gold, L. M. Monteggia, Neuron 
2002, 34, 13-25. 
[39] H. Lehnert, C. Schulz, K. Dieterch, Neurochem. Res. 1998, 23, 1039-1052. 
[40] K. Itoi, A. F. Seasholtz, S. J. Watson, Endocrinol. J. 1998, 45, 13-33. 
[41] M. J. Owens, C. B. Nemeroff, Pharmacol. Rev., 1991, 43, 425-473. 
[42] C. B. Nemeroff, G. Bissette, A. C. Andorn, M. Stanley, Arch. Gen. Psychiatry. 1988, 45, 577-
579. 
[43] F. C. Raadsheer, W. J. Hoogendijk, F. C. Stam, F. J. Tilders, D. F. Swaab, Neuroendocrinology 
1994, 60, 436-444. 
[44] F. Raadasheer, K. Heerikhuize, J. Lucassen, W. Hoogendijk, F. Tilders, D. Swaab, Am. J. 
Psychiat. 1995, 152, 1372-1376 
[45] C. M. Banki, L. Karmacsi, G. Bissette, C. B. Nemeroff, J. Affect. Disorders 1992, 25, 39-45. 
[46] C. B. Nemeroff, G. Bissette, H. Walleus, I. Karlsson, K. Eklund, C. D. Kilts, P. T. Loosen, W. 
W. Vale, Science 1984, 226, 1342-1344. 
[47] L. Arborelius, M. J. Owens, P. M. Plotsky, C. B. Nemeroff, J. Endocrinol. 1999, 160, 1-12. 
[48] F. Holsboer, A. Gerken, U. von Bardekeben, W. Grimm, H. Beyer, O. A. Muller, G. K. Stalla, 
Biol. Psychiatry. 1986, 21, 601-611. 
[49] F. Holsboer, C. J. Lauer, W. Schreiber, J.-L. Krieg, Neuroendocrinology 1995, 62, 340-347. 
[50] M. Joels, E. R. de Kloet, Prog. Neurobiol. 1994, 43, 1-36. 
  19 
[51] K. Inoue, G. R. Valdez, T. M. Reyes, L. E. Reinhardt, A. Tabarin, J. Rivier, W. W. Vale, P. E. 
Sawchenko, G. F. Koob, J. Pharmacol. Exp. Ther. 2003, 305, 385-393. 
[52] M. A. Pelleymounter, M. Joppa, M. Carmouche, M. J. Cullen, B. Brown, B. Murphy, D. E. 
Grigoriadis, N. Ling, A. C. Foster, J. Pharmacol. Exp. Ther. 2000, 293, 799-806. 
[53] T. Skutella, J. C. Probst, U. Renner, F. Holsboer, C. Behl, Neuroscience 1998, 85 (3), 795-805. 
[54] S. Aston-Jones, G. Aston-Jones, G. F. Koob, Psychopharmacology 1984, 84, 28-31. 
[55] H. A. Baldwin, S, Rassnick, J. Rivier, G. F. Koob, K. T. Britton, Psychopharmacology 1991, 
103, 227-232. 
[56] M. E. Carroll, R. A. Meisch, Adv. Behav. Pharmacol. 1984, 4, 47-88. 
[57] P. A. Iredale, J. D. Alvaro, Y. Lee, R. Z. Terwillinger, Y. L. Chen, R. S. Dunman, J. 
Neurochem. 2000, 74, 199-208. 
[58] A. McClusky, J. Garner, P. A. Keller, Bioorg. Med. Chem. 2000, 8, 1213-1223. 
[59] M. Lanier, J. P. Williams, Expert Opin. Ther. Pat., 2002, 12, 1619-1630. 
[60] C. Contoreggi, K. C. Rice, G. Chrousos, Neuroendocrinology, 2004, 80, 111-123. 
[61] D. Grigoriadis, M. Haddach, N. Ling, J. Saunders, Curr. Med. Chem. – CNS Agents 2001, 1, 
63-97. 
[62] D. W. Shulz, R. S. Mansbach, J. Sprouse, J. P. Braselton, J. Collins, M. Corman, A. Dunaiskis, 
S. Faraci, A. W. Schmidt, T. Seeger, P. Seymour, F. D. Tingley, Proc. Natl. Acad. Sci. USA 1996, 
93, 10477-10482. 
[63] A. W. Zobel, T. Nickel, H. E. Kunzel, N. Ackl, A. Sonntag, M. Ising, F. Holsboer, J. 
Psychiatry Res. 2000, 34, 171-181. 
[64] D. A. Gutman, M. J. Owens, K. H. Skelton, K. V. Thrivikraman, C. B. Nemeroff, J. 
Pharmacol. Exp. Ther. 2003, 304, 874-880. 
[65] C. F. Gillespie, C. B. Nemeroff, Psychosom. Med. 2005, 67, Suppl 1: S26-S28. 
 
